FUSEN PHARM: "Enzalutamide Soft Capsules" Approved for Market Launch
I'm PortAI, I can summarize articles.
FUSEN PHARM announced that its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has developed "Enzalutamide Soft Capsules," which have been approved for marketing by the National Medical Products Administration of China. This drug is used for the treatment of high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and metastatic castration-resistant prostate cancer (CRPC) after failure of androgen deprivation therapy. Enzalutamide is an androgen receptor inhibitor that can inhibit the proliferation of prostate cancer cells and induce cell death
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments